-
Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role
•
Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), has recently departed from the Chinese company. He will now serve as Executive Director of External Innovation at AbbVie. Dr. Chen Dong’s Background and Contributions at HengruiDr. Chen Dong studied at Wuhan…
-
Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease
•
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin, a biosimilar version of Johnson & Johnson (J&J)’s auto-immune disease drug Stelara (ustekinumab), has been accepted for review by the National Medical Products Administration (NMPA). The Chinese firm is seeking approval for its use in…
-
J&J Innovative Medicine China Appoints New General Manager and Oncology VP
•
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments to its leadership team. The company has appointed a new general manager and a new vice president. New General ManagerAs of March 1, 2025, Mr. Chen Jian will take on the role of head of…
-
Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder
•
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) announced a proposed change in the actual controller of its controlling shareholder Liaoning Chengda Co., Ltd. The actual controller will change from the State-owned Assets Supervision and Administration Commission of Liaoning Provincial Government to no actual controller. Control Change and Its ImplicationsWith…
-
Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU
•
Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for its drug acoramidis, commercially known as Beyonttra. This near-complete (≥90%) transthyretin (TTR) stabilizer can now be used to treat wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) in the European Union (EU).…
-
Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA
•
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products Administration (NMPA) for its JP-1366 injection to conduct clinical studies in the treatment of peptic ulcer bleeding. This is a significant step forward for the company in the field of gastrointestinal therapeutics. About JP-1366JP-1366 is…
-
Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform
•
US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm Alloy Therapeutics Inc. The alliance is designed to develop a new platform aimed at enhancing Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery…
-
Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval
•
China-based Lifetech Scientific Corporation (HKG: 1302) announced that it has received market approval from the National Medical Products Administration (NMPA) for its aortic stent graft system, co-developed by Fuwai Hospital. Product OverviewThe aortic stent graft system is the first of its kind in China specifically designed for chimney technology. It…
-
Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer
•
Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage radiopharmaceutical company, to develop targeted alpha therapies for various cancers. The partnership will leverage AdvanCell’s Pb-212 production technology and Lilly’s drug development expertise. Collaboration DetailsThe agreement combines AdvanCell’s proprietary radionuclide infrastructure with Lilly’s drug candidate…
-
Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases
•
Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a South Korea-based RNAi therapeutics developer, to jointly develop and commercialize OLX75016, an investigational drug targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications. Drug ProfileOLX75016, derived from a genome-wide association study (GWAS), is…
-
Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology
•
Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for Q4 2024, reaching USD 7.6 billion, driven by strong performance in HIV, oncology, and liver disease segments. Full-year revenues also rose 6% to USD 28.8 billion. Product Performance Geographical Breakdown Outlook for 2025Gilead plans to…
-
Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study
•
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the US Food and Drug Administration (FDA) to initiate a global, multi-center Phase II study for its Liocyx-M00 therapy. The treatment involves autologous T-cells transfected with mRNA encoding hepatitis B surface antigen (HBsAg) specific toll cell…
-
Hainan Poly Pharm’s Generic ProHance Wins FDA Approval in US
•
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced that the US Food and Drug Administration (FDA) has approved its generic version of Bracco’s ProHance (gadoteridol), making it the first and currently only ProHance generic available in the US. The approved strengths include 1.3965 g/5 mL, 2.793 g/10 mL, 4.1895…
-
Kexing Biopharm and Bio-Thera Solutions Form Alliance for Global Expansion
•
China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic alliance to explore international pharmaceutical markets. The partnership aims to leverage the companies’ respective strengths in research and development, manufacturing, and commercialization. Financial details were not disclosed. Bio-Thera’s PortfolioBio-Thera has four marketed biologic drugs: Two…
-
MicroPort MedBot’s Toumai Surgical Robot Wins NMPA Approval for Single-Hole Laparoscopy
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that the National Medical Products Administration (NMPA) has granted market approval for its Toumai single-arm single-hole laparoscopic surgical robot. The device is designed to perform minimally invasive surgeries through a single incision, offering clinical benefits such as reduced scarring and faster…
-
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
•
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused biopharma co-founded with Blackstone Life Sciences in 2019, in a deal valued at up to USD 3.1 billion. The transaction underscores Novartis’ commitment to expanding its pipeline in thrombosis and cardiovascular diseases. Acquisition TermsAnthos shareholders…
-
J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China
•
US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s National Medical Products Administration (NMPA) for two of its biologics: Rybrevant (amivantamab) for non-small cell lung cancer (NSCLC) and Talvey (talquetamab) for multiple myeloma. The approvals mark J&J’s latest expansion in China’s oncology market. Rybrevant…
-
Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials
•
China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and Drug Administration (FDA) has granted clinical clearance for DEG6498, its molecular glue degrader (MGD) targeting human antigen R (HuR). The drug will enter early-stage trials to assess its safety and efficacy in solid tumors. Drug…
-
Roche Transfers InterMune and Esbriet to Legacy Pharma in IP Deal
•
Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8 billion in 2014, and the intellectual property (IP) rights to Esbriet (pirfenidone) in the US to Legacy Pharma Inc. SEZC. Financial terms were undisclosed. FinancialsEsbriet, an idiopathic pulmonary fibrosis (IPF) drug, saw peak sales of…
-
Bio-Thera Solutions’ BAT1006 Wins NMPA Approval for HER2+ Breast Cancer Trial
•
China’s Bio-Thera Solutions Ltd (SHA: 688177) has received clinical trial approval from the National Medical Products Administration (NMPA) for BAT1006, its recombinant humanized monoclonal antibody, in combination with trastuzumab and chemotherapy for HER2-positive unresectable or metastatic breast cancer patients previously treated with antibody-drug conjugates (ADCs). Drug ProfileBAT1006 targets the extracellular…
